Ozempic diarrhea: what the GLP-1 labels report
The short answer
Ozempic diarrhea is on the injection label: in two trials in adults with type 2 diabetes, 8.5% of patients on 0.5 mg and 8.8% on 1 mg reported it, against 1.9% on placebo. All eight GLP-1 labels we track list diarrhea in their tables. Zepbound's reports 19% to 23%, against 8% on placebo. If you can't drink enough to keep up, contact your prescriber.
Key takeaways
- All eight GLP-1 labels list diarrhea in their tables of common reactions.
- Contact your prescriber if diarrhea is frequent or lasting, or if you can't drink enough to keep up.
- The labels link dehydration from diarrhea, nausea or vomiting to acute kidney injury.
- Persistent or severe abdominal pain needs prompt medical attention, because the labels list it as a sign of pancreatitis.
- Don't hold or change a dose on your own. Ask your prescriber.
How often it was reported in the label's trials
| Reaction | Placebon=958 | 5 mgn=630 | 10 mgn=948 | 15 mgn=941 |
|---|---|---|---|---|
| Diarrhea | 8% | 19% | 21% | 23% |
| Reaction | Placebon=235 | 5 mgn=237 | 10 mgn=240 | 15 mgn=241 |
|---|---|---|---|---|
| Diarrhea | 9% | 12% | 13% | 17% |
| Reaction | Placebon=1261 | Wegovy injection 2.4 mg once weeklyn=2116 |
|---|---|---|
| Diarrhea | 16% | 30% |
| Reaction | Placebon=67 | Wegovy injection 2.4 mg once weeklyn=133 |
|---|---|---|
| Diarrhea | 19% | 22% |
| Reaction | Placebon=262 | Ozempic 0.5 mgn=260 | Ozempic 1 mgn=261 |
|---|---|---|---|
| Diarrhea | 1.9% | 8.5% | 8.8% |
| Reaction | Placebon=1576 | 5.5 mgn=1051 | 9 mgn=1055 | 17.2 mgn=1049 |
|---|---|---|---|---|
| Diarrhea | 11% | 21% | 23% | 25% |
| Reaction | Placebon=362 | Semaglutide tablets 7 mgn=356 | Semaglutide tablets 14 mgn=356 |
|---|---|---|---|
| Diarrhea | 4% | 9% | 10% |
| Reaction | Placebon=1941 | Saxendan=3384 |
|---|---|---|
| Diarrhea | 9.9% | 20.9% |
| Reaction | Placebon=126 | Saxendan=125 |
|---|---|---|
| Diarrhea | 14.3% | 22.4% |
| Reaction | Placebon=568 | 0.75 mgn=836 | 1.5 mgn=834 |
|---|---|---|---|
| Diarrhea | 6.7% | 8.9% | 12.6% |
| Reaction | 1.5 mgn=612 | 3 mgn=616 | 4.5 mgn=614 |
|---|---|---|---|
| Diarrhea | 7% | 11.4% | 10.7% |
Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.
If you have diarrhea on a GLP-1 medicine, the thing to watch is dehydration. Contact your prescriber if it’s frequent or lasting, if you can’t drink enough to keep up, or if it arrives together with vomiting. Persistent or severe abdominal pain needs prompt medical attention.
Diarrhea sits in the table of common reactions on every GLP-1 label we track. The label tables on this page give each figure, and the notes below put them in context.
What do the labels report for diarrhea?
Each figure is the share of trial patients who reported diarrhea, next to the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.
- Mounjaro (adults with type 2 diabetes, two pooled placebo-controlled trials): 12% at 5 mg, 13% at 10 mg and 17% at 15 mg, with 9% on placebo.
- Zepbound (adults with obesity or overweight, two pooled trials of up to 72 weeks): 19% at 5 mg, 21% at 10 mg and 23% at 15 mg, with 8% on placebo.
- Foundayo (adults with obesity or overweight, two pooled trials): 21% at 5.5 mg, 23% at 9 mg and 25% at 17.2 mg, with 11% on placebo.
- Wegovy 2.4 mg injection (adults, three weight reduction trials): 30%, with 16% on placebo.
- Saxenda (adults, five trials): 20.9%, with 9.9% on placebo.
- Ozempic injection (adults with type 2 diabetes, two trials): 8.5% at 0.5 mg and 8.8% at 1 mg, with 1.9% on placebo.
- Rybelsus (adults with type 2 diabetes, two trials; the label also covers Ozempic tablets): 9% at 7 mg and 10% at 14 mg, with 4% on placebo.
- Trulicity (adults with type 2 diabetes, pooled trials): 8.9% at 0.75 mg and 12.6% at 1.5 mg, with 6.7% on placebo. In its higher-dose trial, which had no placebo arm: 7.0% at 1.5 mg, 11.4% at 3 mg and 10.7% at 4.5 mg.
In adolescents aged 12 and older with obesity, the Wegovy label reports 22% on 2.4 mg and 19% on placebo, and the Saxenda label reports 22.4% and 14.3%.
One table leaves diarrhea out. Wegovy’s table for the 7.2 mg dose includes only reactions that were more frequent on 7.2 mg than on both 2.4 mg and placebo, and diarrhea isn’t listed there. That tells you about the table’s cutoff. It doesn’t show that diarrhea can’t happen at the higher dose.
Why the placebo column matters here
Diarrhea is common in the general population, and the placebo groups show it. In the Wegovy adolescent trial, 19% of the placebo group reported diarrhea, three points below the treated group. In the Mounjaro pool, the 5 mg group was three points above placebo. In other trials the gap was wider.
The trials differ in who took part, how long they ran and how reactions were counted. So you can’t use these gaps to rank the medicines. What each row does tell you is how that medicine did against its own placebo group.
When does diarrhea occur?
Mostly during dose increases, which the labels call dose escalation. The Zepbound label says the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. Foundayo’s label says the incidence of the same three reactions was higher during the dosage escalation period and decreased over time. The Ozempic and Rybelsus labels say the majority of reports occurred during dose escalation, and Wegovy’s says gastrointestinal (stomach and bowel) reactions were most frequently reported during dosage escalation.
The warning behind it: dehydration and the kidneys
All eight labels carry a warning headed “Acute Kidney Injury Due to Volume Depletion.” Volume depletion means losing too much fluid. Mounjaro’s reads: “There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or MOUNJARO. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.”
In plain words, postmarketing reports are reports made after approval, and hemodialysis is a treatment in which a machine filters the blood.
Two labels report trial figures for this warning. In Zepbound’s pooled trials, acute kidney injury was reported in 0.5% of treated patients and 0.2% on placebo. In Foundayo’s, 0.2% and 0.05%.
The labels also warn that gastrointestinal reactions are sometimes severe. Severe reactions of any gastrointestinal type were reported by 4.1% of adults on Wegovy injection against 0.9% on placebo, and by 4.8% on Saxenda against 1.4% on placebo.
When to contact your prescriber
The Wegovy and Rybelsus labels tell prescribers to monitor kidney function in patients who report reactions that could lead to volume depletion, especially while the dose is being started and raised. That monitoring starts with you reporting it. Contact your prescriber if diarrhea is frequent or lasting, if you can’t drink enough to keep up, or if it arrives together with vomiting. Persistent or severe abdominal pain needs prompt medical attention, because the labels list it as a sign of pancreatitis, an inflammation of the pancreas.
Don’t hold or change a dose on your own. Ask first. For the opposite problem, see constipation, and for all reactions, the GLP-1 side effects guide or the Mounjaro guide.
Frequently asked questions
Does Ozempic cause diarrhea?
The Ozempic injection label lists diarrhea in its table of common side effects. In two trials in adults with type 2 diabetes, 8.5% of patients on 0.5 mg and 8.8% on 1 mg reported it, compared with 1.9% on placebo. The label says most reports of nausea, vomiting and diarrhea came during dose escalation, the weeks when the dose is being raised.
Does Mounjaro cause diarrhea?
The Mounjaro label lists diarrhea in its table of common side effects. In the pool of two placebo-controlled trials in adults with type 2 diabetes, 12% of patients on 5 mg, 13% on 10 mg and 17% on 15 mg reported it. So did 9% of patients on placebo, which means part of what was reported would have occurred without the medicine.
Does Zepbound cause diarrhea?
In Zepbound's two pooled weight reduction trials in adults with obesity or overweight, 19% of patients on 5 mg, 21% on 10 mg and 23% on 15 mg reported diarrhea, compared with 8% on placebo. The label says most nausea, vomiting and diarrhea events occurred during dose escalation (while the dose was being raised) and decreased over time.
Is diarrhea on a GLP-1 dangerous?
The labels treat the dehydration it can cause as the concern. Each one warns of acute kidney injury due to volume depletion (losing too much fluid), and the Zepbound, Mounjaro, Foundayo and Trulicity labels say most reported cases were in patients whose nausea, vomiting or diarrhea led to dehydration. If you can't keep up by drinking, contact your prescriber.
Do people stop treatment because of diarrhea?
A small share do. In the adult Wegovy 2.4 mg trials, diarrhea led 0.7% of patients to stop for good, against 0.1% on placebo. In the adult Saxenda trials it was 1.4%, against 0% on placebo. The other labels report stopping for stomach and bowel reactions as a group, without a separate figure for diarrhea.
Sources (8)
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
Related pages
- GLP-1 side effects: what the FDA labels report
- Ozempic nausea, Zepbound nausea and the other GLP-1 labels
- Vomiting on Wegovy, Zepbound, Ozempic and other GLP-1 medicines
- Ozempic constipation and constipation on other GLP-1 medicines
- Mounjaro (tirzepatide): uses, cost, doses and side effects
- Dyspepsia and indigestion on Zepbound, Wegovy, Mounjaro and other GLP-1 medicines
